3. Alimera Sciences ( ALIM) is a biopharmaceutical company researches, develops, and commercializes prescription ophthalmic pharmaceuticals.
All the six analysts covering the stock recommend buying. In comparison buy ratings for Allergan ( AGN), Regeneron Pharmaceuticals ( REGN), Opko Health ( OPK), QLT ( QLTI), Inspire Pharmaceuticals ( ISPH) and ISTA Pharmaceuticals ( ISTA) are 70%, 64%, 0%, 75%, 11% and 67%, respectively. Analysts polled by Bloomberg foresee the stock gaining around 25% over the next 12 months at a consensus target price of $12.7.